The European Commission has approved Lynparza (olaparib) for use in patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer within the European Union, it was revealed by AstraZeneca and MSD in a July 8, 2020 press release.
Approval for the therapy was based on the results